首页> 美国卫生研究院文献>Journal of Diabetes Investigation >Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial

【2h】

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial

机译：在日本2型糖尿病患者中每日两次地格胰岛素/门冬胰岛素与双相门冬胰岛素30的比较：一项随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aims/IntroductionInsulin degludec/insulin aspart (IDegAsp) is a soluble combination of insulin degludec (70%) and insulin aspart (30%). The present exploratory trial investigated the safety of switching unit‐to‐unit from twice‐daily basal or pre‐mix insulin to twice‐daily IDegAsp in Japanese patients with type 2 diabetes.

机译：目的/简介地格胰岛素/门冬胰岛素（IDegAsp）是胰岛素地格胰岛素（70％）和门冬胰岛素（30％）的可溶组合。本探索性试验研究了在日本2型糖尿病患者中，从每天两次的基础胰岛素或预混胰岛素切换到每天两次的IDegAsp的安全性。

著录项

期刊名称 Journal of Diabetes Investigation
作者
Yukiko Onishi; Kenichi Yamada; Jeppe Zacho; Jan Ekelund; Yasuhiko Iwamoto;
展开▼
作者单位

展开▼
年(卷),期 2017(8),2
年度 2017
页码 210–217
总页数 8
原文格式 PDF
正文语种
中图分类基础医学;
关键词
Insulin degludec/insulin aspart Japanese Type 2 diabetes;

机译：地格曲胰岛素/门冬胰岛素;日本;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial [J] . Onishi Yukiko, Yamada Kenichi, Zacho Jeppe, Journal of diabetes investigation. . 2017,第2期

机译：在日本2型糖尿病患者中，每天两次地格胰岛素/门冬胰岛素与双相门冬胰岛素30两次：一项随机对照试验
2. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial [J] . Kaneko Shizuka, Chow Francis, Choi Dong Seop, Diabetes research and clinical practice . 2015,第1期

机译：在基础或预混合/预混合胰岛素控制不充分的亚洲2型糖尿病患者中，地格曲胰岛素/门冬胰岛素与双相门冬胰岛素30对比：一项为期26周，针对治疗目标的随机试验
3. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: A phase 3a, randomized, treat-to-target trial [J] . Fulcher,G.R., Christiansen,J.S., Bantwal,G., Diabetes care . 2014,第8期

机译：未控制，经胰岛素治疗的2型糖尿病中地格曲松/门冬胰岛素和双相门冬胰岛素30的比较：A期3a，随机，靶向治疗
4. Comparing artificial pancreas controlled by hybrid "closed-loop" machine learning (ML) trained algorithm to multi-daily injection (MDI), insulin pump without CGM and "sensor assisted" insulin pump therapies for Diabetes Type 1 (DT1) treatment [C] . Joan Carles Peiró International Conference on Data Analytics for Business and Industry: Way Towards a Sustainable Economy . 2020

机译：将通过混合“闭环”机器学习（ML）控制的人工胰腺培训算法对多日注于多日注射（MDI），胰岛素泵而没有CGM和“传感器辅助”胰岛素泵疗法1型（DT1）处理
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin‐naïve adults with Type 2 diabetes [O] . E. Franek, M. Haluzík, S. Canecki Varžić, -1

机译：与未接受过胰岛素治疗的2型糖尿病成年人中的双相胰岛素aspart 30相比每日两次地格胰岛素/门冬胰岛素可提供更好的空腹血糖控制和降低的低血糖发生率
7. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial [O] . ??? 2015

机译：门冬胰岛素/门冬胰岛素与门冬胰岛素30相比，亚洲2型糖尿病患者基础或前/自混胰岛素控制不当：一项为期26周的随机，治疗目标试验

Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅